

THE WALL STREET JOURNAL | **MarketWatch** | [More](#) |

Welcome, please [sign in](#).
[My Portfolio](#) • [Community](#) • [VSE](#) • [Alerts](#)


MarketWatch

FRONT PAGE | **NEWS & COMMENTARY**

[Columnists](#) | [First Take](#) | [Special Reports](#) | [Blogs](#) | [Podcasts](#) | [Industry News](#) | [Economy & Politics](#) | [Newsletters](#) | [Election 2008](#)

LATEST NEWS | [\[AIG\] S&P: Review on most AIG ratings revised to 'developing'](#)

Before the Bell E-newsletter

 Get a daily, pre-market look at all the stocks expected to move, plus all the early news and action in Europe and Asia.

[Privacy policy](#)


MOST POPULAR

READ | **E-MAILED** | **EDITOR'S PICK**

1. [Money market fund breaks the buck, freezes redemptions](#)
2. [How bad is it? It's actually pretty darn good](#)
3. [U.S. stock indexes plummet as fate of financials questioned](#)
4. [Stock decline could force Morgan to pursue merger: report](#)
5. [AIG gets Fed rescue in form of \\$85 billion loan](#)
6. [Gold surges as investors rush to safety](#)
7. [Barclays snaps up Lehman business for \\$1.75 billion](#)
8. [Stock futures slip after U.S. government's AIG rescue plan](#)
9. [AIG's businesses for sale as bailout buys insurer time](#)
10. [Uncle Sam blinks, steps in to bail out AIG](#)

[Get the Latest MarketWatch News >>](#)

PARTNER CENTER

 Switch to Scottrade, get up

InNexus Biotechnology Strengthens Patent Team With New Leadership

Last update: 9:25 a.m. EDT Sept. 9, 2008

BRITISH COLUMBIA, Canada, Sept 09, 2008 /PRNewswire-FirstCall via COMTEX/ -- InNexus Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF, <http://www.ixsbio.com>), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, welcomes David Warden to its Board of Directors.

Mr. Warden was a founding partner of Yetter, Warden & Coleman, L.L.P. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to antitrust, securities violations, trade secrets, patents, and other business and technology litigation.

"I am pleased to have David join our team as a director on our Board," said Jeff Morhet, Chairman and CEO. "His broad legal experience and, in particular, his expertise in patent law will prove valuable as we continue to expand and fortify our intellectual property position. I look forward to working with David as a valuable addition to our Board."

Mr. Warden is considered one of Houston's top Lawyers from H magazine and recognized as one of the Texas "Super Lawyers" in Texas Monthly magazine from 2003-2006. Warden has published many articles during his career, "Trade Secrets and Patents: Comparison and Contrasts in Royalty Determination," and "How to Quantify Trade Secrets Theft," are among them. He received his B.S. and his M.S. in Engineering from Purdue University and obtained his Juris Doctorate degree in 1981 from the University of Virginia.

InNexus has taken deliberate steps to enhance its intellectual property position. This latest addition follows a previous appointment of Gilbert Gabo, as the company's Vice President of Operations and Director of Legal Affairs. Mr. Gabo was a practicing patent attorney with the law firm of Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C. before joining the company and also brings a decade of operations experience from his work as a product engineer. He received his J.D. in 2001 from the University of Detroit Mercy Law School and his B.S. in Engineering in 1993 from the University of Michigan in Ann Arbor.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit <http://www.ixsbio.com>.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE InNexus Biotechnology Inc.

<http://www.ixsbio.com>

Copyright (C) 2008 PR Newswire. All rights reserved ■



| | |
|--|---------------------------------------|
| Now pay \$8.95. Get the works. LEARN MORE GO > charles SCHWAB | Take our free online seminars. |
| E*TRADE | Get 100 Commission-Free |
| The Proactive Fund Investor with Bill Donoghue | Bull and bear strategies. Free Trial. |
| Hulbert INTERACTIVE Take the tour! | Unlock stock, fund and newsletter |
| Where Small Business has a Big Voice. WSJ.com | Visit WSJ.com/smallbusiness |

Sponsored Links

British Columbia

Free Download. Instant access to British Columbia & more.
eWossToolbar.com/BritishColumbia

Biotech Quality Software

Biotech Quality Processes to Comply with FDA Regulations
www.mastercontrol.com

Biotechnology

Find Local & Nation Sites Options for Biotechnology
www.Spicksearch.com

Top stories

- 14 minutes ago [Gold surges as investors rush to safety](#)
- 1:41 PM today [U.S. stock indexes plummet as fate of financials questioned](#)
- 2:45 PM today [AIG's businesses for sale as bailout buys insurer time](#)

[Site Index](#) | [Topics](#) | [Archive](#) | [Help](#) | [Feedback](#) | [Media Archive](#) | [Premium Products](#) | [Mobile](#) | [RSS](#) | [Podcasts](#) | [Company Info](#) | [Advertising Media Kit](#) | [DJ Client Solutions](#)

The Wall Street Journal Digital Network:
[WSJ.com](#) | [Barron's Online](#) | [BigCharts](#) | [Virtual Stock Exchange](#) | [All Things Digital](#) | [MarketWatch Community](#)
[RealEstateJournal.com](#) | [Financial News Online](#) | [WSJ.com Small Business](#)

MarketWatch

Copyright © 2008 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the [Terms of Service](#) and [Privacy Policy](#).

InNexus Biotechnology Strengthens Patent Team With New Leadership - MarketWatch

Intraday data provided by [Interactive Data Real Time Services](#), a division of Interactive Data Corp. and subject to [terms of use](#). Historical and current end-of-day data provided by [Interactive Data Pricing and Reference Data](#). More information on [NASDAQ traded symbols](#) and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.